New paper published about anti-influenza activity of CI-1040

Our scientific founders published a new paper on antiviral action of MEK inhbitors in Antiviral Research, the highest-ranking journal in the area of antiviral therapy and the fourth-highest in the general field of virology.

The paper is entitled: "The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a prolonged treatment window compared to standard of care in vivo."

You can download the paper here: Download

Media Coverage

 

Events & Presentations

Please note that, due to the current coronavirus crisis, many conferences have been canceled or postponed.

  • September 21-24, 2020 - BioPharm America Digital. Dr. Björn Cochlovius, VP Business Development, will represent the Company and be available for networking and one-on-one meetings.
  • October 26-29, 2020 - BIO-Europe Digital.

Feel free to contact us any time.

Address

Atriva Therapeutics GmbH
Eisenbahnstr. 1, 72072 Tübingen

+49 (0)7071 8597673
info@atriva-therapeutics.com

LinkedIn
Twitter

In order to be able to design our website in the best possible way and to continuously improve it, we are using cookies. By continuing to use our website, you permit the use of cookies. More information can be found in our data protection rules.